

Sulfonamide and sulfamide substituted imidazoquinolines**Publication number:** CN1354663 (A)**Publication date:** 2002-06-19**Inventor(s):** CROOKS S L [US]; LINDSTROM K J [US]; MERRILL B A [US] +**Applicant(s):** 3M INNOVATIVE PROPERTIES CO [US] +**Classification:****- International:** A61K31/437; A61K31/4745; A61K31/496; A61K31/541; A61K45/06; A61K9/00; A61P31/12; A61P35/00; A61P37/02; C07D471/04; A61K31/4353; A61K31/4738; A61K31/496; A61K31/541; A61K45/00; A61K9/00; A61P31/00; A61P35/00; A61P37/00; C07D471/00; (IPC1-7): A61K31/437; A61K31/4745; C07D471/02**- European:** A61K31/4745; A61K45/06; A61K9/00M18D; A61K9/00M18E; C07D471/04; A61K31/4745**Application number:** CN20008008683 20000608**Priority number(s):** US19990138365P 19990610; US20000589216 20000607**Also published as:**

CN1249061 (C)

WO0076519 (A1)

US6331539 (B1)

US2003130299 (A1)

US6825350 (B2)

[more >>](#)

Abstract not available for CN 1354663 (A)

Abstract of corresponding document: WO 0076519 (A1)

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Data supplied from the **espacenet** database — Worldwide